How to Read an S-1

What an S-1 actually is

Form S-1 is the SEC's general-purpose registration statement, used by companies going public for the first time. It contains the full prospectus — the legally operative document delivered to investors when shares are sold. The S-1 is the single most comprehensive disclosure any private company ever makes; 10-Ks that follow have less narrative depth.

The S-1 goes through multiple rounds of SEC review (each round produces an S-1/A amendment) before being declared effective. Once effective, the company files a 424B variant with the final priced terms and starts trading.

Why the S-1 is harder to read than a 10-K

Three reasons:

1. No track record to compare against. For a public company, year-over-year diffs reveal trends. For an IPO, you have one snapshot.
2. Marketing meets disclosure. S-1s are drafted by the company and underwriters with a clear interest in selling the offering. Tone is often more aspirational than 10-K disclosures.
3. Forward-looking statements are minimal. Unlike de-SPAC mergers (which historically allowed projections), S-1s restrict forward-looking content heavily — leaving you with historical data to extrapolate from.

The remedy: read S-1s as deposition transcripts, not press releases. What is the company forced to disclose that it would prefer not to? That is the signal.

Section reference: what to read and prioritize

The amendment-counting heuristic

When a company first files an S-1, the SEC issues comments — usually within 30 days. The company addresses them in an S-1/A (amendment) and refiles. This loop repeats until the SEC declares the registration effective.

Typical patterns:

• 2-3 amendments, 3-6 month timeline — normal
• 4-5 amendments, 6-9 month timeline — moderate friction; investigate
• 6+ amendments, 9+ month timeline — often signals accounting, projections, or risk-factor disputes
• Withdrawal then refile — usually a serious signal worth deep investigation

The actual amendment text on EDGAR is informative — each S-1/A shows changes since the prior version. Pay particular attention to: changes in Risk Factors (additions = SEC pushed back), changes in revenue-recognition footnote (accounting friction), and changes in use-of-proceeds language (often softens specificity through review).

Use-of-proceeds parsing

The Use of Proceeds section discloses where IPO cash will go. The specificity is the signal:

• Highly specific("$120M to repay Series D preferred, $80M to fund Brazil expansion through 2027, $50M for general corporate purposes") — you know what management plans
• Moderately specific("working capital and general corporate purposes; possibly future acquisitions") — typical, OK
• Vague("general corporate purposes" alone) — common with WKSI-style follow-ons; concerning for an IPO
• Largely secondary (proceeds go mostly to existing shareholders, not the company) — read carefully; you are providing exit liquidity, not growth capital

Customer-concentration disclosures

The Business section of an S-1 must disclose customers representing 10%+ of revenue. This is often the most undervalued line of analysis available to retail investors.

What to look for:

• One customer 30%+ of revenue — that customer is the business; renewal terms matter enormously
• Top 5 customers 70%+ of revenue — single defection can crater the business
• Largest customer is itself a VC-funded startup — concentration risk compounded by counterparty risk
• Contract length disclosed: month-to-month — much riskier than 3-year contracts

Compare across years (the S-1 shows 2-3 years of customer data) to see if concentration is increasing or decreasing. Growing concentration is a yellow flag.

Related-party transactions — most under-read section

Disclosed transactions between the company and its directors, officers, large pre-IPO shareholders, or their family members. This section is rarely read but often the most informative single page in the S-1.

Pattern matters more than amount. Watch for:

• Company leases real estate from founder's LLC — read the rent terms vs. market
• Co-founder spouse on payroll as consultant — usually benign but worth noting
• Loans to/from executives — should normally be zero post-Sarbanes-Oxley
• Services from related party that don't pass at-arms-length test — yellow flag

S-1 red flags

1. 6+ S-1 amendments over 9+ months. SEC review friction is usually substantive, not procedural.
2. Going-concern language in audit report. Rare in IPOs but devastating when present.
3. Material weakness in internal controls disclosed. Common in early-stage IPOs but a signal that financial reporting may need restatement post-listing.
4. Dual-class with supervoting (10-to-1+) and founder under 40. Reduces shareholder accountability for decades. Not disqualifying but priced into long-term holding decision.
5. Use of proceeds: 60%+ to selling shareholders. You're funding existing investors' exit, not company growth. Sometimes legitimate, often not.
6. Largest customer disclosed as >40% of revenue, no long-term contract. One renewal cycle from a crisis.
7. Auditor changed within 12 months pre-IPO. Often a reason — read prior 8-K Item 4.01 (if public predecessor exists) or any S-1 disclosure about reportable events.

The 30-minute S-1 read

You will never fully read a 300-page S-1. Focused 30 minutes beats dabbling 3 hours. Workflow:

1. 2 min — Count S-1/A amendments + measure timeline from initial S-1 to most recent amendment.
2. 10 min — Read Risk Factors in full. Most have 30-50 specific risks; skim, but mark anything specific to this business (vs. generic industry risk).
3. 5 min — Read Use of Proceeds. Note specificity. Note whether company or selling shareholders receive proceeds.
4. 5 min — Read Customer Concentration disclosure in Business section. Note top customer % and contract length.
5. 5 min — Read Related-Party Transactions in full. Often only 2-3 pages, often the most revealing 2-3 pages.
6. 3 min— Skim MD&A revenue and margin narrative. Compare growth rate against guidance.

Frequently asked questions

Related glossary terms

• s-1
• 424b
• ipo
• prospectus
• s-3
• s-4
• spac
• wksi
• risk-factors
• md-a